Arrowhead Official Reaffirms 2010 Calando Partnership Goal

"If data from the [ongoing] clinical trial continue to be positive, the value of such a deal could increase as the trial progresses," Arrowhead President and CEO Christopher Anzalone said in a letter to company shareholders.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.